Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Sponsor
Hellenic Society of Hematology
Study ID
NCT03746652
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will assess the efficacy of daratumumab in combination with ixazomib and dexamethasone as second line treatment for relapsed Multiple Myeloma patients.

Key Dates

Start date
Dec 31, 2018
Status verified
Nov 2018
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: DId
    Daratumumab, Ixazomib, Dexamethasone

Primary Outcome Measure

Overall Response Rate (ORR) [ Time Frame: From first day of treatment until end of study, documented progressive disease (PD), or death (approximately up to 36 months) ]

Central Contacts

Related Studies